Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 96 shares, a decrease of 73.7% from the September 30th total of 365 shares. Based on an average daily trading volume, of 2 shares, the short-interest ratio is currently 48.0 days. Currently, 0.0% of the shares of the company are short sold.
Basilea Pharmaceutica Stock Performance
OTCMKTS BPMUF opened at $76.25 on Wednesday. The business’s fifty day moving average is $76.75 and its 200 day moving average is $69.45. Basilea Pharmaceutica has a fifty-two week low of $59.29 and a fifty-two week high of $77.40.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Switzerland-based biopharmaceutical company focused on discovering, developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology indications. The company is headquartered in Basel and was established in 2000 as a spin-off from Roche.
Basilea’s principal products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive fungal infections, and Zevtera (ceftobiprole), a cephalosporin antibiotic developed for several serious bacterial infections.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
